Assembled modular complexes for targeted drug delivery can be based on strong non-covalent interactions between a cargo module containing an adapter protein and a docking tag fused to a targeting protein. We have recently constructed a completely humanized adapter/docking tag system based on interactions between 15 amino acid (Hutag) and 110 amino acid (HuS) fragments of human ribonuclease I (RNase I). Although recombinant HuS can be expressed and refolded into a functionally active form, the puri®cation procedure is cumbersome and expensive, and more importantly, it yields a signi®cant proportion of improperly folded proteins. Here we describe engineering, high-yield expression, and puri®cation of a chimeric bovine/human RNase (BH-RNase) comprising 1±29 N-terminal amino acids of bovine ribonuclease A and 30± 127 amino acids of human RNase I. Unlike RNase I, the chimeric BH-RNase can be cleaved by either subtilisin or proteinase K between A20 and S21, providing a functionally active HuS. The HuS obtained from chimeric BHRNase differs from wild-type HuS by an N24T substitution; therefore, we have reverted this substitution by mutating N24 to T24 in BH-RNase. This BH-RNase mutant can also be cleaved by subtilisin or proteinase K yielding wild-type HuS. The af®nity of HuS obtained from BH-RNase to Hu-tag is approximately ®ve times higher than that for recombinant HuS, re¯ecting a higher percentage of properly folded proteins.
Introduction
Lack of ef®cient technology for loading drugs onto targeting proteins hinders advances in targeted drug delivery (Dubowchik and Walker, 1999) . Most loading technologies are based on random chemical conjugation of a`cargo' (such as drugs, drug carriers or adapters for drug carriers) directly to targeting proteins. Chemical modi®cations of targeting proteins damage their ability to bind to cellular targets, require expensive custom development and yield heterogeneous preparations.
We have recently proposed a novel strategy for modular assembly of targeting complexes for drug delivery (Backer et al., 2002a) . This technology avoids chemical modi®cation of targeting proteins by using a standardized docking system that includes two modules: a`docking' tag fused to a targeting protein and a`payload' module containing an adapter protein for binding to the docking tag. Standardized payload modules are pre-made by linking a cargo to an adapter (Figure 1) .
A proof-of-principle for this strategy was obtained with a docking system based on interactions between two fragments of bovine ribonuclease A (RNase A), an N-terminal 1±15 amino acid peptide (S-peptide) and a C-terminal 21±124 amino acid fragment (S-protein) serving as an adapter (Backer et al., 2002a) . Association of these fragments reconstitutes RNase activity and interactions between these fragments are being used for af®nity puri®cation and detection of recombinant proteins fused to S-peptide (Kim and Raines, 1993) . Since fragments of bovine RNase A are potentially immunogenic in humans, as RNase A is immunogenic in mice (Matousek et al., 2002) , we have recently developed a docking system based on interactions between similar fragments of human pancreatic ribonuclease I (RNase I), that we named Hu-peptide and HuS [ (Backer et al., 2003) ; see Sorrentino and Libonati (Sorrentino and Libonati, 1997) , for a review on human RNases]. It should be noted that attempts to express a native 21±127 amino acid RNase I fragment in Escherichia coli were not successful, and the only variant that was synthesized in E.coli was an 18±127 HuS(P19A, S20A) with the P19A and S20A amino acid substitutions. Recombinant 18±127 HuS(P19A, S20A) was recovered from inclusion bodies and refolded into a functionally active conformation in the presence of synthetic Hu-peptide. After removal of Hu-peptide, puri®ed 18±127 HuS(P19A, S20A) retained the ability to bind Hu-peptide and Hu-tagged fusion proteins with restoration of ribonuclease activity. Attempts to refold this protein or, for that matter, recombinant bovine Sprotein, into functionally active conformations without the corresponding peptides were not successful (Backer et al., 2002b (Backer et al., , 2003 . This is a somewhat cumbersome and expensive strategy for preparing the quantities of HuS that are necessary for preclinical and early clinical studies. Here we describe a strategy for making native 21±127 amino acid HuS using an engineered chimeric bovine/human RNase (BH-RNase) as a starting material. This strategy is based on a procedure developed for preparation of S-protein via subtilisin cleavage of RNase A Chimeric ribonuclease as a source of human adapter protein for targeted drug delivery Protein Engineering vol. 16 no. 10 pp. 771±775, 2003 DOI: 10.1093 between A20 and S21 (Richards and Vithayathil, 1959) . Unfortunately, limited proteolytic cleavage of RNase I does not release HuS, presumably because of incompatibility of the hinge loop 15±25 with the subtilisin active center (Gupta et al., 1999; Pous et al., 2001) . To reconstruct a cleavage site in this loop, we have constructed BH-RNase containing 1±29 amino acids of RNase A and 30±127 amino acids of RNase I. The 21± 29 region of RNase A differs from a corresponding region of RNase I by the presence of N24 instead of T24. In order to reconstruct wild-type RNase I sequence starting from S21, we have also constructed a mutant BH-RNase (N24T). We found that both chimeric RNases can be expressed at a high level, refolded into an enzymatically active conformation, and cleaved by either subtilisin or proteinase K between A20 and S21. The af®nity of HuS obtained from BH-RNase to Hutagged proteins is~5-fold higher than that of recombinant 18±127 HuS(P19A, S20A), re¯ecting a higher proportion of functionally active protein.
Materials and methods

Construction of chimeric RNase
The pET-HP plasmid encoding 1±127 amino acids of human RNase I (el-Joubary et al., 1999) was a generous gift from Dr G.D'Alessio (Napoli Federico II University, Naples, Italy). The ORF of an 18±125 fragment of human RNase I with the T24N amino acid substitution was ampli®ed by PCR using a 5¢-ATGTCCGCTGCCAGCAGCTCCAACTACTGCAACCAG-ATGATGCGTCG-3¢ sense primer (mutation underlined) and an antisense primer, 5¢-CTATTCAACACACGCGTCGAA-ATGAACCGG-3¢. The PCR product was cloned in the pETBlue-1 using a Perfectly Blunt Cloning Kit (Novagen), and the T24N mutation was con®rmed by sequencing. Then, 10 bovine RNase A codons were introduced by PCR using a sense primer, 5¢-TTTGAGCGGCAGCACATGGACTCCAGCAC-TTCCGCTGCCAGCAGCTCC-3¢. An antisense primer, 5¢-TCAAGAGTCTTCAACAGACGCGTCG-3¢, introduced codons for D126, S127 and a stop-codon. The PCR product was cloned in the pETBlue-1 and the resulting construct was con®rmed by sequencing. Seven more bovine codons were introduced in the sequence by amplifying it with a sense primer, 5¢-ATGAAGGAAACTGCAGCAGCCAAGTTT-GAGCGGCAGCACATGGACTCC-3¢ and the above antisense primer. The PCR product was cloned in the pETBlue-1 and con®rmed by sequencing. The 1±29 B/ 30±127 H-RNase coding sequence was ampli®ed by PCR using a sense primer, 5¢-CACAAGCATATGAAGGAAACTGCAGCAGCC-AAG-3¢ (NdeI site underlined) and an antisense primer, 5¢-TACGGTACCTCAAGAGTCTTCAACAGACGCGTCG-3¢ (KpnI site underlined), and cloned in NdeI±KpnI sites of the pET29a(+) bacterial expression vector (Novagen). The N24T amino acid substitution was introduced in the pET29/ 1±29 B/ 30±127 H-RNase plasmid DNA by site-directed mutagenesis using a Gene-Tailor Site Directed Mutagenesis Kit (Invitrogen), a sense primer, 5¢-TCCGCTGCCAGCAGC-TCCACCTACTGCAACCAG-3¢ (mutation underlined) and an antisense primer, 5¢-GGAGCTGCTGGCAGCGGA-AGTGCTGGAG-3¢. The N24T mutation was con®rmed by sequencing. Puri®cation of HuS Both 1±29 B/ 30±127 H-RNase (BH-RNase) and 1±29 B/ 30±127 H-N24T-RNase (BH-N24T) were expressed in BL21(DE3) E.coli (Novagen), refolded from inclusion bodies, and puri®ed by ion-exchange chromatography on a HiTrap SP-Fast Flow column (Amersham) and RP-HPLC on C8 as described for recombinant RNase I (Backer et al., 2003) . To exchange buffer, RP-HPLC puri®ed proteins were loaded on a HiTrap SP-Fast Flow column equilibrated with a buffer containing 20 mM NaOAc pH 6.5 and eluted with a buffer containing 20 mM NaOAc, 0.6 M NaCl, pH 6.5. BH-RNase and its mutant were digested with either subtilisin or proteinase K (Sigma) at a protein to protease ratio of 100:1 (w/w) at room temperature or at 4°C. Bovine peptide was removed from the digestion mixture by RP-HPLC on a C18 column as described (Backer et al., 2002b (Backer et al., , 2003 . After buffer exchange on a HiTrap SP-Fast Flow column performed as described above, HuS-T24N and wild-type HuS were puri®ed by af®nity chromatography on a Hu-peptide column. The column was prepared by coupling of a CA-extended Hu-peptide (CA-KESRAKKFQRQHMDS synthesized by Genemed Synthesis, Inc., South San Francisco, CA) to Activated Thiol Sepharose 4B (Amersham) according to the manufacturer's protocol. Before coupling, CA-Hu-peptide was treated with 100 mM TCEP for 30 min at room temperature, puri®ed on an RP-HPLC C18 column, and transferred into conjugation buffer via buffer exchange on a HiTrap SP-Fast Flow column. Bound HuS was eluted from the af®nity column with 0.2 M citric acid. After buffer exchange on a HiTrap SP-Fast Flow column (as described above), proteins were aliquoted and stored at ±70°C.
HuS/Hu-tag binding assay
The equilibrium dissociation constant (K D ) values for HuS-T24N/Hu±peptide complexes were determined as described (Backer, 2002b (Backer, , 2003 . Brie¯y, HuS-T24N at ®nal concentrations of 0.1, 0.2 or 0.3 nM was mixed with varying amounts of Hu-tagged vascular endothelial growth factor [Hu-VEGF, expressed as described in Backer et al. (Backer et al., 2002a) ] in a buffer containing 20 mM Tris±HCl, 100 mM NaCl, pH 7.5, 0.1 mg/ml poly C and incubated for 5 min at room temperature. The activities of the reconstituted ribonucleases were measured by the absorbance at 280 nm of the reaction mixtures cleared from TCA-precipitated material. One optical unit of TCAsoluble material released from poly C incubated with reconstituted ribonuclease was de®ned as one relative unit of ribonuclease activity. Calculations of the K D values were performed assuming that the initial rate of the hydrolysis is proportional to the concentration of reconstituted ribonuclease. DYNAFIT software was used for the global ®tting with numeric iteration and calculation of the K D values (Kuzmic, 1996) .
Results
Construction and expression of BH-RNase
Bovine RNase A is cleaved by subtilisin between A20 and S21 yielding functionally active S-protein (Richards and Vithayathil, 1959) . In contrast, limited proteolytic cleavage of human RNase I does not release HuS, presumably because of incompatibility of the hinge loop 15±25 with the subtilisin active center, most likely due to a conformational change induced by P19 (Gupta et al., 1999; Pous et al., 2001) . Indeed, direct comparison of the bovine and human hinge loops 15±25 backbones (Figure 2A , shown in green and red respectively) revealed signi®cant differences between the two RNases.
In order to develop an RNase-based source of HuS, we have constructed a chimeric BH-RNase containing a 1±29 amino acid fragment of RNase A and a 30±127 amino acid fragment of RNase I ( Figure 2B and C) . We reasoned that a preferential cleavage of the peptide bond between A20 and S21 by subtilisin might take place in BH-RNase. The 21±29 region of RNase A differs from a corresponding region of RNase I by the presence of N24 instead of T24. In order to reconstruct the wild-type RNase I sequence starting from S21, we have also constructed a mutant BH-N24T.
Both BH-RNase and BH-N24T were expressed in E.coli strain BL21(DE3), recovered from inclusion bodies, refolded by a two-step dialysis, and puri®ed via ion-exchange and reverse-phase chromatography as described previously for recombinant RNase I (Backer et al., 2003) . Puri®ed BH-RNase and BH-N24T had typical yields of 60±80 mg/l, and were found to be >98% pure judging by SDS±PAGE ( Figure 2D , for BH-RNase) and HPLC (data not shown). Ribonuclease activities of BH-RNase and BH-N24T were indistinguishable, both were~2-fold lower than that of recombinant RNase I (prepared as described in Backer et al., 2003) , and varied from isolation to isolation within 20% (data not shown).
BH-RNase cleavage
Initially, limited proteolytic digestion of BH-RNase with subtilisin was performed at the BH-RNase/protease ratio of 100:1 (w/w) at room temperature. A BH-RNase fragment with an electrophoretic mobility corresponding to that of HuS was transiently accumulated within 1 h under these conditions ( Figure 3A, top) . However, signi®cant quantities of BH-RNase were degraded by 30±60 min of incubation. Lowering the incubation temperature to 4°C signi®cantly reduced the reaction rate and enhanced the selective proteolysis of the A20±S21 peptide bond, yielding more HuS(T24N) (Figure 3A , bottom).
To further increase the yield of HuS(T24N), we have tested proteinase K that was shown to cleave the A20±S21 bond of RNase A more ef®ciently then subtilisin (Markert et al., 2001) . 
Adapter protein for targeted drug delivery
Indeed, we found that limited proteolysis of BH-RNase with proteinase K yielded more HuS(N24T) than subtilisin after a 4 h treatment under the same conditions ( Figure 3A, bottom) . Interestingly, the BH-N24T mutant that yields wild-type HuS was more resistant to proteinase K than BH-RNase ( Figure 3B ). HuS puri®cation Short peptides released from BH-RNase and BH-N24T during proteolysis were removed from digestion mixtures by RP-HPLC on a C8 column as described for separation of human Speptide and recombinant 18±127 HuS(P19A, S20A) (Backer et al., 2003) . In order to separate HuS fragments from undigested ribonucleases we used an af®nity column that was constructed by coupling of a CA-extended Hu-peptide (CA-KESRAKKFQRQHMDS). After passing reaction mixtures through this column, undigested RNase and minor fragments were found in¯ow-through fractions, whereas HuS fragments bound to the column were eluted with 0.2 M citric acid (Figure 4 , for BH-RNase cleavage). Q-TOF ES MS con®rmed the identity of HuS(T24N) (MW 12 146) as a main product obtained from BH-RNase. In addition, 5±10% of puri®ed protein resulted from the cleavage at the S21±S22 bond, as was reported for RNase A (Neumann and Hofsteenge, 1994; Mendez et al., 2000) .
HuS activity
To characterize the af®nity of puri®ed HuS(T24N) to Hupeptide, we used VEGF fused to Hu-tag [Hu-VEGF, expressed as described in Backer et al. (Backer et al., 2003) ]. Reconstituted ribonuclease activity in HuS/Hu-VEGF mixtures was measured under conditions of equilibrium between free and bound HuS(T24N) as described (Backer et al., 2002b (Backer et al., , 2003 . To derive equilibrium dissociation constant (K D ) values for these complexes, the experimental data were analyzed with DYNAFIT software for the global ®tting with numeric iteration and calculation of the K D values (Kuzmic, 1996) under an assumption that the initial rate of the hydrolysis is proportional to the concentration of reconstituted ribonuclease. We found that the af®nity of HuS(T24N) to Hu-VEGF was characterized by a K D value of 29.3 T 2.6 nM ( Figure 5) . These values are approximately ®ve times lower that that obtained for complexes between recombinant 18±127 HuS(P19A, S20A) and Hu-VEGF under the same experimental conditions (K D of 162 T 16 nM; Backer et al., 2003) . To explain this difference, we have tested what proportion of 18±127 HuS(P19A, S20A) binds to the Hu-peptide af®nity column and found that only 20±30% of this protein was retained on the column (data not shown). The latter result supports the notion that the difference in K D values is due to signi®cant heterogeneity of refolded recombinant 18±127 HuS(P19A, S20A) as compared with HuS preparations.
Discussion
Here we report engineering of the ®rst chimeric BH-RNase that combines 29 N-terminal amino acid residues of bovine RNase A fused to 97 C-terminal residues of human RNase I (Figure 2 ). The choice of N-terminus from bovine RNase A is based on the classic work by Richards and Vithayathil (Richards and Vithayathil, 1959) who found that limited proteolysis of RNase A with subtilisin yields two complimentary fragments known as S-peptide and S-protein [for a review of RNase A, see Raines (Raines, 1998) ]. Neither S-peptide nor S-protein alone has enzymatic activity, but reconstitute active ribo- N24T mutant were cleaved with proteinase K. The BH-RNase/protease ratio was 100:1 (w/w). Samples saved at various incubation times were analyzed by SDS±PAGE on 17.5% gels followed by SafeBlue staining. (N24T) and Hu-VEGF was tested and the K D value was calculated as described (Backer et al., 2002b (Backer et al., , 2003 . nuclease upon forming a complex known as RNase S. Subsequent studies established that subtilisin and proteinase K cleave RNase A preferentially between A20 and S21, with minor products formed upon cleavage of nearby peptide bonds (Rauber et al., 1978; Neumann and Hofsteenge, 1994; Mendez et al., 2000; Markert et al., 2001) . The sensitivity of the hinge loop 15±25 to proteolytic cleavage varies between closely related mammalian pancreatic RNases, re¯ecting signi®cant sequence diversity in this particular region [for a discussion see Gupta et al. (Gupta et al., 1999) and Figure 2 for comparison between RNase A and RNase I]. For example, hinge regions of rat pancreatic RNase (Gupta et al., 1999) and human RNase I (Pous et al., 2001) do not ®t into the catalytic center of subtilisin.
We found that BH-RNase and its N24T mutant are cleaved by both subtilisin and proteinase K at the A20±S21 bond, yielding functionally active HuS fragments. The conditions of cleavage and af®nity puri®cation on the S-peptide column are optimized to achieve a 40±50% yield of HuS fragments from chimeric RNases (Figures 3 and 4) . Importantly, HuS displays an~5-fold higher af®nity to Hu-tagged proteins than 18±127 HuS(P19A, S20A) [ Figure 5 and Backer et al. (Backer et al., 2003) ]. This change might be a result of more homogeneous preparations of HuS that arise upon proteolytic cleavage of chimeric RNase. Indeed, surface plasmon resonance experiments and af®nity chromatography on the S-peptide column suggest that refolded 18±127 HuS(P19A, S20A) exists in several conformations with different af®nities to Hu-peptide (Backer et al., 2003) .
We found that the BH-N24T mutant appeared to be more resistant to proteolytic cleavage by subtilisin and proteinase K (Figure 3 ). This result is somewhat surprising, since molecular modeling indicates that an amino acid in position 24 is not involved in direct interactions with a catalytic triad in subtilisin or proteinase K (data not shown). Unfortunately, this resistance did not lead to a higher yield of wild-type HuS. Nevertheless, since wild-type HuS might be more advantageous in minimizing the risk of an adverse immunological response in potential clinical applications of the adapter/docking tag system, experiments to optimize its production are in progress.
Taken together, our data indicate that chimeric BH-RNase is a superior source of an adapter protein for assembled complexes for targeted drug delivery. Our recent experiments with tumor radionuclide imaging using techetium-99m labeled HuS/Hu-VEGF complexes suggest important new applications for this system (F.Blankenberg et al., manuscript in preparation).
